Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer

doi:10.3748/wjg.v26.i44.7022

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 44

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5510)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

312

WORD

180

HTML

2621

Figures (1-1)

270

Tables (1-6)

282

Sum=3665

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

543

Download

1302

Sum=1845

Nov 28, 2020 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Nov 28, 2020; 26(44): 7022-7035
Published online Nov 28, 2020. doi: 10.3748/wjg.v26.i44.7022

Table 1 Predictive factor for response of preoperative chemoradiation therapy for rectal cancer in the literature

Ref.	Study design	pCR (%)	Related factor with response of preoperative CRT	Independent factor for pCR
Restivo et al[7], 2013	Prospective (n = 260)	16.5%		CEA < 5 ng/mL and distance from anal verge > 5 cm
Huh et al[8], 2013	Retrospective (n = 391)	14.6%	Noncircumferential tumors, nonmacroscopic ulceration, WELL differentiation, Early T, N stage, low level of pretreatment CEA	Tumor circumferentiality, macroscopic ulceration, pretreatment CEA < 5 ng/mL
Wallin et al[9], 2013	Retrospective (n = 469)	20.0%		Pretreatment CEA ≤ 5 ng/mL
Kleiman et al[10], 2015	Prospective (n = 141)	13.5%		Low post CRT CEA level, normalization of CEA from initial elevated; CEA level
Hu et al[11], 2018	Prospective (n = 146)	15.0%	CEA exponential decrease group between pretreatment and during-CRT: Higher rates of downstaging and pCR	CEA clearance pattern
Yamamoto et al[12], 2019	Prospective (n = 111)		Combination of lymphocyte to monocyte ratio (LMR) and ypN; status: poor prognosis	Low pretreatment LMR ypN(+)

pCR: Pathologic complete response; CEA: Carcinoembryonic antigen; CRT: Chemoradiation treatment.

Table 2 Patient characteristics

Characteristics	Distribution
Age (yr, mean ± SD)	60.1 ± 10.9
Sex
Male	99 (73.3%)
Female	36 (26.7%)
BMI (kg/m², mean ± SD)	22.9 ± 3.1
Smoker	46 (34.1%)
ASA
1	80 (59.3%)
2	40 (29.6%)
3	14 (10.4%)
4	1 (0.7%)
Distance of tumor from the anal verge (cm, mean ± SD)	6.4 ± 3.0
Pre-CRT CEA (ng/mL, mean ± SD)	18.1 ± 45.0
Pre-CRT tumor size (cm, mean ± SD)	4.6 ± 1.4
Pre-CRT TNM stage
I	1 (0.7%)
II	13 (9.6%)
III	121 (89.6%)
Curative resection after CRT
Low anterior resection	64 (47.4%)
Ultra-low anterior resection	17 (12.6%)
Abdominoperineal resection	46 (34.1%)
Hartmann operation	7 (5.2%)
Total colectomy	1 (0.7%)
Radiation dose, cGy	5040
Interval from preoperative CRT to operation (wk)	7.8 ± 1.7
Post-CRT CEA (ng/mL)	4.8 ± 8.1
Down-staging after preoperative CRT	60 (44.4%)
Pathologic complete response	27 (20.0%)
Adjuvant chemotherapy	121 (89.6%)
Follow-up (mo)	60.4 ± 24.3

SD: Standard deviation; BMI: Body mass index; ASA: American Society of Anesthesiology; CEA: Carcinoembryonic antigen; TNM: Tumor Node Metastasis; CRT: Chemoradiotherapy. I

Table 3 Comparison of the changes in the carcinoembryonic antigen level before and after chemoradiotherapy

Variables	Group A (n = 27)	Group B (n = 43)	Group C (n = 65)	P value
Age, yr				> 0.999
< 65	17 (63.0%)	27 (62.8%)	41 (63.1%)
≥ 65	10 (37.0%)	16 (37.2%)	24 (36.9%)
Sex				0.358
Male	21 (77.8%)	34 (79.1%)	44 (67.7%)
Female	6 (22.2%)	9 (20.9%)	21 (32.3%)
ASA				0.734
< 3	23 (85.2%)	38 (88.4%)	59 (90.8%)
≥ 3	4 (14.8%)	5 (11.6%)	6 (9.2%)
Pre-CRT tumor size (cm)	4.6 (3.7-5.0)	4.5 (4.0-5.1)	4.3 (3.8-5.0)	0.515
Pre-CRT CEA (ng/mL)	25.8 (10.6-70.7)	11.3 (6.8-21.3)	2.4 (1.8-3.3)	< 0.001
Pre-CRT NLR				0.983
< 2.8	17 (63.0%)	28 (65.1%)	42 (64.6%)
≥ 2.8	10 (37.0%)	15 (34.9%)	23 (35.4%)
Pre-CRT PLR				0.132
< 138.2	11 (40.7%)	19 (44.2%)	39 (60.0%)
≥ 138.2	16 (59.3%)	24 (55.8%)	26 (40.0%)
Pre-CRT T stage				0.217
T3	18 (66.7%)	34 (79.1%)	54 (83.1%)
T4	9 (33.3%)	9 (20.9%)	11 (16.9%)
Pre-CRT N stage				0.021
N0	1 (3.7%)	1 (2.3%)	11 (16.9%)
N+	26 (96.3%)	42 (97.7%)	54 (83.1%)
Pre-CRT TNM stage				0.021
I	1 (3.7%)	0	0
II	1 (3.7%)	1 (2.3%)	11 (16.9%)
III	25 (92.6%)	42 (97.7%)	54 (83.1%)
Post-CRT CEA (ng/dL)	8.4 (6.0–13.7)	2.9 (2.0–4.0)	1.8 (1.2–2.9)	< 0.001
Post-CRT T stage				0.001
0–2	3 (11.1%)	5 (11.6%)	25 (38.5%)
3–4	24 (88.9%)	38 (88.4%)	40 (61.5%)
Post-CRT N stage				0.006
N0	8 (29.6%)	20 (46.5%)	42 (64.6%)
N+	19 (70.4%)	23 (53.5%)	23 (35.4%)
Post-CRT M stage				0.090
0	25 (92.6%)	42 (97.7%)	65 (100%)
1	2 (7.4%)	1 (2.3%)	0
Post-CRT TNM Stage				0.008
0	0	0	2 (3.1%)
I	2 (7.4%)	4 (9.3%)	19 (29.2%)
II	5 (18.5%)	15 (34.9%)	21 (32.3%)
III	19 (66.7%)	23 (53.5%)	23 (35.4%)
IV	2 (7.4%)	1 (2.3%)	0
Down-staging on MRI after CRT				0.013
No	21 (77.8%)	25 (58.1%)	29 (44.6%)
Yes	6 (22.2%)	18 (41.9%)	36 (55.4%)

Group A: Patients with pre- and post-CRT CEA levels > 5 ng/mL; Group B: Patients with pre- and post-CRT CEA levels > 5 and ≤ 5 ng/mL, respectively; Group C: Patients with pre- and post-CRT CEA levels ≤ 5 ng/mL. ASA: American Society of Anesthesiology; CRT: Chemoradiotherapy; CEA: Carcinoembryonic antigen; NLR: Neutrophil–lymphocyte ratio; PLR: Platelet–lymphocyte ratio; TNM: Tumor Node Metastasis; MRI: Magnetic resonance imaging.

Table 4 Comparison of the changes in the carcinoembryonic antigen level after curative resection

Variables	Group A (n = 27)	Group B (n = 43)	Group C (n = 65)	P value
Name of surgery				0.272
Low anterior resection	15 (55.6%)	22 (51.2%)	43 (66.2%)
Others¹	12 (44.4%)	21 (48.8%)	22 (33.8%)
Differentiation				0.781
Well–Moderate	8 (29.6%)	13 (30.2%)	16 (24.6%)
Poorly + others²	19 (70.4%)	30 (69.8%)	49 (75.4%)
Lymphovascular invasion				0.444
No	22 (81.5%)	35 (81.4%)	58 (89.2%)
Yes	5 (18.5%)	8 (18.6%)	7 (10.8%)
Perineural invasion				0.005
No	21 (77.8%)	38 (88.4%)	64 (98.5%)
Yes	6 (22.2%)	5 (11.6%)	1 (1.5%)
Postoperative T stage				< 0.001
0–2	2 (7.4%)	11 (25.6%)	38 (58.5%)
3–4	25 (92.6%)	32 (74.4%)	27 (41.5%)
Postoperative N stage				0.538
N0	15 (55.6%)	27 (62.8%)	44 (67.7%)
N+	12 (44.4%)	16 (37.2%)	21 (32.3%)
Postoperative M stage				0.002
M0	24 (88.9%)	43 (100%)	65 (100%)
M1	3 (11.1%)	0	0
Postoperative TNM stage				< 0.001
0	0	3 (7.0%)	25 (38.5%)
I	2 (7.4%)	5 (11.6%)	8 (12.3%)
II	13 (48.1%)	19 (44.2%)	11 (16.9%)
III	9 (33.3%)	16 (37.2%)	21 (32.3%)
IV	3 (11.1%)	0	0
CEA on postoperative day 7	3.7 (2.8-5.2)	1.6 (1.1-2.2)	1.1 (0.7-1.7)	< 0.001
Tumor regression grade				< 0.001
0	1 (3.7%)	3 (7.0%)	26 (40.0%)
1	7 (25.9%)	23 (53.5%)	18 (27.7%)
2	11 (40.7%)	14 (32.6%)	17 (26.2%)
3	8 (29.6%)	3 (7.0%)	4 (6.2%)
Good response (TRG 0,1)				0.003
TRG 0, 1	8 (29.6%)	26 (60.5%)	44 (67.7%)
TRG 2, 3	19 (70.4%)	17 (39.5%)	21 (32.3%)
Pathologic complete response				< 0.001
pCR (-)	27 (100%)	41 (95.3%)	40 (61.5%)
pCR (+)	0	2 (4.7%)	25 (38.5%)

Group A: patients with pre- and post-CRT CEA levels > 5 ng/mL; Group B: patients with pre- and post-CRT CEA levels > 5 and ≤ 5 ng/mL, respectively; and Group C: patients with pre- and post-CRT CEA levels ≤ 5 ng/mL. Name of surgery,

¹others abdominoperineal resection, Hartmann’s operation, subtotal or total colectomy; Differentiation,

²others mucinous, signet ring cell. TNM: Tumor Node Metastasis; CEA: Carcinoembryonic antigen; TRG: Tumor regression grade.

Table 5 Comparison of the non- pathologic complete response and pathologic complete response groups after the chemoradiotherapy following surgical resection

Variables	Non-pCR (n = 108)	pCR (n = 27)	P value
Pre-CRT tumor size (cm, mean ± SD)	4.7 ± 1.5	4.4 ± 1.3	0.246
Pre-CRT CEA, ng/mL			< 0.001
CEA ≤ 5	40 (37.0%)	25 (92.6%)
CEA > 5	68 (63.0%)	2 (7.4%)
Pre-CRT T stage			0.875
T3	84 (77.8%)	22 (81.5%)
T4	24 (22.2%)	5 (18.5%)
Pre-CRT N stage			0.004
N0	6 (5.6%)	7 (25.9%)
N+	102 (94.4%)	20 (74.1%)
Pre-CRT TNM stage			0.005
I	1 (0.9%)	0
II	6 (5.6%)	7 (25.9%)
III	101 (93.5%)	20 (74.1%)
Post-CRT CEA, ng/mL			0.008
≤ 5	81 (75.0%)	27 (100%)
> 5	27 (25.0%)	0
Downstaging after CRT			0.051
No	65 (60.2%)	10 (37.0%)
Yes	43 (39.8%)	17 (63.0%)
Differentiation			> 0.999
Well–Moderate	30 (27.8%)	7 (25.9%)
Poor + others¹	78 (72.2%)	20 (74.1%)
Lymphovascular invasion			0.034
No	88 (81.5%)	27 (100%)
Yes	20 (18.5%)	0
Perineural invasion			0.151
No	96 (88.9%)	27 (100%)
Yes	12 (11.1%)	0

¹Mucinous, signet ring cell, pCR: Pathologic complete response; CRT: Chemoradiotherapy; SD: Standard deviation; CEA: Carcinoembryonic antigen; TNM: Tumor node metastasis.

Table 6 Multivariate analysis for prognostic markers to predict the response to the chemoradiotherapy

	Pathologic complete response		Good response (TRG 0,1)
	OR (95%CI)	P value	OR (95%CI)	P value
Sex (female vs male)	0.26 (0.08–0.80)	0.022
Pre-CRT CEA (> 5 vs ≤ 5 ng/mL)	18.71 (4.62–129.51)	< 0.001
Pre-CRT NLR (≥ 2.8 vs < 2.8)	5.27 (1.55–22.55)	0.013	2.82 (1.27–6.48)	0.013
Post-CRT CEA (> 5 vs ≤ 5 ng/mL)			5.07 (1.92–14.83)	0.002
Post-CRT T stage (≥ T3 vs < T3)	3.25 (1.09–9.97)	0.036	3.28 (1.23–9.90)	0.023
Postop differentiation (poorly¹vs well-mod.)			3.41 (1.35–9.48)	0.013

¹Mucinous, signet ring cell, OR: Odds ratio; CI: Confidence interval; TRG: Tumor regression grade; CRT: Chemoradiotherapy; CEA: Carcinoembryonic antigen; NLR: Neutrophil–lymphocyte ratio.

Citation: Cheong C, Shin JS, Suh KW. Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer. World J Gastroenterol 2020; 26(44): 7022-7035
URL: https://www.wjgnet.com/1007-9327/full/v26/i44/7022.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i44.7022